CRISPR/Cas9-Based Screening of FDA-Approved Drugs for NRF2 Activation: A Novel Approach to Discover Therapeutics for Non-Alcoholic Fatty Liver Disease. Here, NFE2L2 is linked to metabolic dysfunction-associated steatotic liver disease.